表紙
市場調查報告書

腸炎:開發中產品分析

Enterocolitis - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 293885
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
腸炎:開發中產品分析 Enterocolitis - Pipeline Review, H2 2019
出版日期: 2019年12月16日內容資訊: 英文 54 Pages
簡介

所謂腸炎是指大腸及小腸的發炎。主要的症狀,有發熱和腹部膨脹、噁心、腹瀉、直腸出血、倦怠感等。腸炎的要素,有腸內組織的發炎,及胃內容排出遲緩,腹壁部的紅斑症,無呼吸發作,化膿症,心血管虛脫等。主要的治療方法中包含著抗生素等。

本報告提供全球各國的腸炎(全腸炎,小腸結腸炎)治療用的開發中產品的開發情形相關分析,開發中產品的開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查。

簡介

  • 調查範圍

腸炎概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品:各企業
  • 開發中產品:各大學/機關
  • 企業開發中的產品
  • 大學/機關研究中的產品

腸炎:治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

腸炎的開發治療藥的企業

  • AvidBiotics Corp.
  • Infant Bacterial Therapeutics AB
  • Leadiant Biosciences Inc

藥物簡介

腸炎:暫停中的計劃

腸炎:產品開發里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11620IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Enterocolitis - Pipeline Review, H2 2019, provides an overview of the Enterocolitis (Gastrointestinal) pipeline landscape.

Enterocolitis is an inflammation of the large and small intestines. Symptoms include fever, abdominal swelling, nausea, diarrhea, rectal bleeding and sluggishness. Causes of enterocolitis include Inflammation of the intestinal tissues, delayed gastric emptying, abdominal wall erythema, apnea, sepsis and cardiovascular collapse. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Enterocolitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Enterocolitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Enterocolitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Enterocolitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Enterocolitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Enterocolitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Enterocolitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Enterocolitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Enterocolitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Enterocolitis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Enterocolitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Enterocolitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Enterocolitis - Overview
  • Enterocolitis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Enterocolitis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Enterocolitis - Companies Involved in Therapeutics Development
  • Avexegen Therapeutics Inc
  • Glycohub Inc
  • Glycosyn LLC
  • Infant Bacterial Therapeutics AB
  • Leadiant Biosciences Inc
  • Liminal BioSciences Inc
  • Noveome Biotherapeutics Inc
  • Plakous Therapeutics Inc
  • Scioto Biosciences Inc
  • Synthetic Biologics Inc
  • Worphmed Srl
  • Enterocolitis - Drug Profiles
  • alpha-1 proteinase inhibitor (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • C-34 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IBP-9414 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • melatonin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NRG-4 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PROTEGO-PD - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SB-121 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Necrotizing Enterocolitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ST-266 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • STP-206 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SYN-020 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Enterocolitis - Dormant Projects
  • Enterocolitis - Product Development Milestones
  • Featured News & Press Releases
  • Jul 05, 2019: Infant Bacterial enrols first patient in NEC study
  • May 19, 2019: FDA and Infant Bacterial Therapeutics agree on the design of Phase III study
  • Mar 05, 2019: Infant Bacterial Therapeutics announces first distribution agreement
  • Nov 21, 2018: The Phase 3 study protocol is modified after IBT's meeting with the FDA
  • Nov 09, 2018: IBTs Chief Scientific Officer invited to speak at NEC Society Symposium 2019
  • May 15, 2018: Infant Bacterial Therapeutics: Interim Management Statement, January 1 - March 31, 2018
  • Mar 05, 2018: Prometic receives Rare Pediatric Disease Designation from U.S. FDA for its Inter-Alpha-Inhibitor-Proteins
  • Feb 15, 2018: Prometic granted orphan drug designation by FDA for Inter-Alpha-Inhibitor-Proteins for treatment of necrotizing enterocolitis (NEC)
  • Dec 11, 2017: Infant Bacterial Therapeutics presents data from its Safety and Tolerability Study in premature infants
  • Nov 23, 2017: Infant Bacterial Therapeutics Interim Management Statement, January 1 - September 29, 2017
  • Sep 28, 2017: European Medicines Agency adopts a positive opinion on the Paediatric Investigation Plan for IBT's lead product
  • Sep 11, 2017: Infant Bacterial Therapeutics announces that top line data demonstrate similar safety and tolerability profile in the active and placebo groups
  • Jan 24, 2017: Last patient enrolled in IBT's Phase 2 study
  • Nov 21, 2016: Positive recommendation from the independent Data Safety Monitoring Board to continue Phase II Study
  • Jun 07, 2016: Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Enterocolitis, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Enterocolitis - Pipeline by Avexegen Therapeutics Inc, H2 2019
  • Enterocolitis - Pipeline by Glycohub Inc, H2 2019
  • Enterocolitis - Pipeline by Glycosyn LLC, H2 2019
  • Enterocolitis - Pipeline by Infant Bacterial Therapeutics AB, H2 2019
  • Enterocolitis - Pipeline by Leadiant Biosciences Inc, H2 2019
  • Enterocolitis - Pipeline by Liminal BioSciences Inc, H2 2019
  • Enterocolitis - Pipeline by Noveome Biotherapeutics Inc, H2 2019
  • Enterocolitis - Pipeline by Plakous Therapeutics Inc, H2 2019
  • Enterocolitis - Pipeline by Scioto Biosciences Inc, H2 2019
  • Enterocolitis - Pipeline by Synthetic Biologics Inc, H2 2019
  • Enterocolitis - Pipeline by Worphmed Srl, H2 2019
  • Enterocolitis - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Enterocolitis, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top